A scientific statement from the American Heart Association was published in Circulation, with the purpose of providing a thorough review of available evidence on HIV-associated cardiovascular disease.
The FDA has granted Breakthrough Therapy designation to apabetalone in combination with standard of care therapy for the secondary prevention of MACE in patients with T2Dm and recent ACS.
Lower use of low-dose aspirin for the primary prevention of cardiovascular disease (CVD) in blacks vs whites may partly account for racial discrepancies in the incidence of ischemic cardiac death.
